EMCURE / NSE / Biotechnology & Drugs
Emcure Pharmaceuticals
1Y Price Trend
Key Information
Recommendations
RatingStrong Buy
Target High1,830.35
Target Low1,230
Target Mean1.33
Target Median41.67
Risk Metrics
Overall RiskBalanced risk
Board Risk35.5
Key Analysis
Overall score, performance score, return rating, defensive, aggressive, and balanced views.
Download appProjection Analytics
Best-case, base-case, worst-case, and dynamic AI projection views.
Download appLatest stock news
Emcure FY26 revenue rises 16.6% to ₹9,204 crore, PAT grows 33.1% scanx.trade
Emcure Pharmaceuticals Investor Presentation Highlights June 2026 Performance and Future Outlook InvestyWise
Emcure Pharmaceuticals Ltd Valuation Shifts Signal Caution Amid Strong Returns MarketsMojo
Emcure Pharmaceuticals shares rise nearly 4% after Bain Capital divests 2% stake; everything you need to know Upstox
BC Investments Sells Rs 612 Crore Stake in Emcure Pharma; Kotak Mahindra Mutual Fund Acquires Shares - Pretax Income Report newsline.com
Stocks to watch, June 10: Afcons Infra, NLC India, Ajanta Pharma, Emcure Pharma, Adani Green, oil-sensitives Upstox
Stocks in news: Emcure Pharma, Dixon Technologies, Ajanta Pharma, Godrej Properties, Vedanta The Economic Times
Kotak Mahindra MF buys Rs 612 crore worth Emcure shares from Bain Capital, promoter sells 2.8% stake in... Moneycontrol.com
© SharekeyX | Rusaka Technologies 2024-2026